NCT03752541: Allogeneic T-cells with Anti-BCMA CAR - BCMA-UCART in RRMM - Chinese study

NCT03752541: Efficacy and Safety Evaluation of BCMA-UCART

AllogeneicT-cells with Anti-BCMA CAR

Chimeric Antigen Receptor）in the Treatment of Relapsed or Refractory Multiple Myeloma

This trial aims to evaluate the safety and efficacy of BCMA-UCART in treating patients with relapsed or refractory multiple myeloma.

Sponsor

Bioray Laboratories

Collaborators

Shanghai Tongji Hospital, Tongji University School of Medicine

Second Xiangya Hospital of Central South University

---

ClinicalTrials.gov Identifier: NCT03752541

Efficacy and Safety Evaluation of BCMA-UCART（Allogeneic Engineered T-cells Expressing Anti-BCMA Chimeric Antigen Receptor）in the Treatment of Relapsed or Refractory Multiple Myeloma

First Posted : November 26, 2018

Click here for details on ClinicalTrials.gov

---

CART - BCMA : National Cancer Institute

Biological: BCMA-UCART

---

Location

China, Shanghai

Shanghai Tongji Hospital